Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response

被引:17
作者
Thammanichanond, Duangtawan [1 ]
Moneer, Sarah [1 ]
Yotnda, Patricia
Aitken, Campbell [2 ]
Earnest-Silveira, Linda [3 ]
Jackson, David [1 ]
Hellard, Margaret [2 ]
McCluskey, James [1 ]
Torresi, Joseph [3 ]
Bharadwaj, Mandvi [1 ]
机构
[1] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia
[2] Macfarlane Burnet Inst Med Res & Publ Hlth, Melbourne, Vic 3004, Australia
[3] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
recombinant adenoviral constructs; hepatitis C virus; vaccine;
D O I
10.1016/j.clim.2008.04.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTLs) play an important rote in HCV clearance. The frequency of HCV-specific T-CD8 in peripheral blood of HCV-infected donors is very low and HCV cannot be cultivated for reinfection of antigen presenting cells, making it difficult to detect TCD8 of broad HCV specificities from peripheral blood mononuclear cells (PBMCs). We have developed a recombinant adenoviral system that efficiently reactivates and expands HCV-specific CTLs from PBMCs of HCV-infected donors. Replication-incompetent adenoviruses expressing individual HCV proteins (core and NS3) were produced and PBMCs from HCV-infected donors were transduced with these recombinant adeno-HCV constructs to stimulate HCV-specific CTL populations. T cells expanded from adeno-HCV stimulated cultures were potent producers of HCV-specific IFN-gamma and TNF-alpha and efficiently lysed target cells pulsed with HCV peptides. These constructs could stimulate TCD8 directed towards multiple HCV peptides while preserving the determinant hierarchy. This approach therefore overcomes some of the shortcomings of the selective expansion of CTLs with peptide-based vaccine strategies. These findings provide an effective approach for the expansion of HCV-specific CTLs from PBMCs of HCV-infected patients and have potential for immunotherapeutic/vaccine development. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:329 / 339
页数:11
相关论文
共 28 条
[1]   Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J].
Abbink, Peter ;
Lemckert, Angelique A. C. ;
Ewald, Bonnie A. ;
Lynch, Diana M. ;
Denholtz, Matthew ;
Smits, Shirley ;
Holterman, Lennart ;
Damen, Irma ;
Vogels, Ronald ;
Thorner, Anna R. ;
O'Brien, Kara L. ;
Carville, Angela ;
Mansfield, Keith G. ;
Goudsmit, Jaap ;
Havenga, Menzo J. E. ;
Barouch, Dan H. .
JOURNAL OF VIROLOGY, 2007, 81 (09) :4654-4663
[2]  
AITKEN CK, 2007, MOL EPIDEMIOLOGY HEP
[3]   Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus [J].
Arribillaga, L ;
Sarobe, P ;
Arina, A ;
Gorraiz, M ;
Borrás-Cuesta, F ;
Ruiz, J ;
Prieto, J ;
Chen, LP ;
Melero, I ;
Lasarte, JJ .
VACCINE, 2005, 23 (27) :3493-3499
[4]   Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene [J].
Casimiro, DR ;
Chen, L ;
Fu, TM ;
Evans, RK ;
Caulfield, MJ ;
Davies, ME ;
Tang, A ;
Chen, MC ;
Huang, LY ;
Harris, V ;
Freed, DC ;
Wilson, KA ;
Dubey, S ;
Zhu, DM ;
Nawrocki, D ;
Mach, H ;
Troutman, R ;
Isopi, L ;
Williams, D ;
Hurni, W ;
Xu, Z ;
Smith, JG ;
Wang, S ;
Liu, X ;
Guan, LM ;
Long, R ;
Trigona, W ;
Heidecker, GJ ;
Perry, HC ;
Persaud, N ;
Toner, TJ ;
Su, Q ;
Liang, XP ;
Youil, R ;
Chastain, M ;
Bell, AJ ;
Volkin, DB ;
Emini, EA ;
Shiver, JW .
JOURNAL OF VIROLOGY, 2003, 77 (11) :6305-6313
[5]   Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro [J].
Diao, J ;
Smythe, JA ;
Smyth, C ;
Rowe, PB ;
Alexander, IE .
GENE THERAPY, 1999, 6 (05) :845-853
[6]   Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine [J].
Duraiswamy, J ;
Bharadwaj, M ;
Tellam, J ;
Connolly, G ;
Cooper, L ;
Moss, D ;
Thomson, S ;
Yotnda, P ;
Khanna, R .
CANCER RESEARCH, 2004, 64 (04) :1483-1489
[7]   Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma [J].
Hoffmann, Dennis ;
Bayer, Wibke ;
Heim, Albert ;
Potthoff, Anja ;
Nettelbeck, Dirk M. ;
Wildner, Oliver .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (04) :988-998
[8]   Improved gtioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses [J].
Hoffmann, Dennis ;
Meyer, Bernhard ;
Wildner, Oliver .
JOURNAL OF GENE MEDICINE, 2007, 9 (09) :764-778
[9]   High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection [J].
Lauer, GM ;
Barnes, E ;
Lucas, M ;
Timm, J ;
Ouchi, K ;
Kim, AY ;
Day, CL ;
Robbins, GK ;
Casson, DR ;
Reiser, M ;
Dusheiko, G ;
Allen, TM ;
Chung, RT ;
Walker, BD ;
Klenerman, P .
GASTROENTEROLOGY, 2004, 127 (03) :924-936
[10]   HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor-α [J].
Lichterfeld, M ;
Yu, XG ;
Waring, MT ;
Mui, SK ;
Johnston, MN ;
Cohen, D ;
Addo, MM ;
Zaunders, J ;
Alter, G ;
Pae, E ;
Strick, D ;
Allen, TM ;
Rosenberg, ES ;
Walker, BD ;
Altfeld, M .
BLOOD, 2004, 104 (02) :487-494